använder sig av cookies för att ge dig som besökare en så bra upplevelse som möjligt.
10 June 2019

Commissioned research: Xbrane Biopharma AB

OUTPERFORM: We initiate coverage on Xbrane Biopharma with a stepwise valuation approach. For the twelve months ahead, to mid-2020, we see a reasonable valuation range of SEK 45-55 per share. Towards mid-2021, we see a reasonable valuation range between SEK 57-71 per share.

Biosimilar drug development with a first focus on Lucentis (ranibizumab)
Xbrane Biopharma was founded in 2008 in Stockholm, Sweden, and is a late-stage drug development company focusing on biosimilars. It became a publicly listed company in 2016 and in Q2 2018, the company entered into a strategic collaboration with Stada, Germany, covering the development and commersialisation of Xlucane, Xbrane’s biosimilar to the reference medicine Lucentis (ranibizumab). Xbrane’s earlier stage development portfolio includes a biosimilar to UCB’s Cimzia (certolizumab) and other biosimilars.

Click here to download report

Marketing material commissioned by Xbrane Biopharma AB